BRAF and NRAS mutations (which are important treatment targets in malignant melanoma) are not usually observed in CCS, although there is an exceptional CCS case that harbored BRAF mutation and responded to BRAF-targeted therapy [103]. Here, BRAF is linked to melanoma.